Eupraxia Pharmaceuticals Inc.
EPRX.TOTSXHealthcare● Active
$8.43
+$0.10(+1.20%)
Market Cap$302953412
P/E Ratio—
52W High$12.86
52W Low$5.2
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EPRX.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.31
Est. -$0.26 · -18.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS
EPRX.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.31 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$0.26 | -$0.31 | -18.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 19, 2026 | -$0.21 | -$0.44 | -111.1% | — | — | — |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.22 | -$0.24 | -9.4% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.25 | -$0.24 | +3.8% | — | — | — |
| ▼ Q2 FY2025 | May 6, 2025 | -$0.23 | -$0.30 | -30.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.16 | -$0.28 | -75.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.19 | -$0.23 | -21.1% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$0.31
EPS Est.
-$0.26
EPS Surpr.
-18.1%
Revenue
—
Q1 FY2026
Mar 19, 2026Miss
EPS Actual
-$0.44
EPS Est.
-$0.21
EPS Surpr.
-111.1%
Revenue
—
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.24
EPS Est.
-$0.22
EPS Surpr.
-9.4%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.24
EPS Est.
-$0.25
EPS Surpr.
+3.8%
Revenue
—
Q2 FY2025
May 6, 2025Miss
EPS Actual
-$0.30
EPS Est.
-$0.23
EPS Surpr.
-30.4%
Revenue
—
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.16
EPS Surpr.
-75.0%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.19
EPS Surpr.
-21.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-1.04 | $-1.04 | $-1.04 | 3 |
| Q3 FY2028 | $-0.80 | $-0.80 | $-0.80 | 3 |
| Q2 FY2028 | $-0.32 | $-0.32 | $-0.32 | 3 |
| Q1 FY2028 | $-0.33 | $-0.33 | $-0.33 | 3 |
| Q4 FY2027 | $-0.36 | $-0.36 | $-0.36 | 2 |
| Q3 FY2027 | $-0.35 | $-0.35 | $-0.35 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -18.1% | $10.12 | $10.51 | +3.85% |
| ▼ Q1 FY2026 | Mar 19, 2026 | -111.1% | $10.31 | $10.50 | +1.84% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -9.4% | $8.47 | $7.75 | -8.50% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +3.8% | $7.33 | $7.45 | +1.64% |
| ▼ Q2 FY2025 | May 6, 2025 | -30.4% | $5.51 | $5.54 | +0.54% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -75.0% | $5.65 | $5.55 | -1.77% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -21.1% | $4.36 | $4.41 | +1.15% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +0.0% | $3.40 | $3.41 | +0.29% |
Q2 FY2026+3.85%
Report Date
May 12, 2026
EPS Beat/Miss
-18.1%
Price Before
$10.12
Price After
$10.51
Q1 FY2026+1.84%
Report Date
Mar 19, 2026
EPS Beat/Miss
-111.1%
Price Before
$10.31
Price After
$10.50
Q4 FY2025-8.50%
Report Date
Nov 4, 2025
EPS Beat/Miss
-9.4%
Price Before
$8.47
Price After
$7.75
Q3 FY2025+1.64%
Report Date
Aug 12, 2025
EPS Beat/Miss
+3.8%
Price Before
$7.33
Price After
$7.45
Q2 FY2025+0.54%
Report Date
May 6, 2025
EPS Beat/Miss
-30.4%
Price Before
$5.51
Price After
$5.54
Q1 FY2025-1.77%
Report Date
Mar 20, 2025
EPS Beat/Miss
-75.0%
Price Before
$5.65
Price After
$5.55
Q4 FY2024+1.15%
Report Date
Nov 7, 2024
EPS Beat/Miss
-21.1%
Price Before
$4.36
Price After
$4.41
Q3 FY2024+0.29%
Report Date
Aug 7, 2024
EPS Beat/Miss
+0.0%
Price Before
$3.40
Price After
$3.41
Avg Beat Reaction+0.96%
Avg Miss Reaction-0.48%
Beat Rate2 / 8 quarters
Largest Move-8.50% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EPRX.TO ends December
Eupraxia Pharmaceuticals Inc. (EPRX.TO) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.31 — missing the analyst consensus of $-0.26 by -18.1%. The next EPRX.TO earnings date is expected around September 1, 2026.
Each quarter, investors track EPRX.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EPRX.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EPRX.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EPRX.TO earnings · 5 questionsEupraxia Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. EPRX.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EPRX.TO historically reports after market close (AMC).
EPRX.TO earnings datewhen is EPRX.TO earningsEPRX.TO next earnings datewhen does EPRX.TO report earningsEPRX.TO earnings calendar
▸ Source: FMP · Eupraxia Pharmaceuticals Inc. SEC filings · US GAAP · Eupraxia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026